Minimum Information About a Bioactive Entity (MIABE)

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2011 Sep 1

PMID 21878981

Citations 37

Authors

Sandra Orchard

Bissan Al-Lazikani

Steve Bryant

Dominic Clark

Elizabeth Calder

Ian Dix

Ola Engkvist

Mark Forster

Anna Gaulton

Michael Gilson

Robert Glen

Martin Grigorov

Kim Hammond-Kosack

Lee Harland

Andrew Hopkins

Christopher Larminie

Nick Lynch

Romeena K Mann

Peter Murray-Rust

Elena Lo Piparo

Christopher Southan

Christoph Steinbeck

David Wishart

Henning Hermjakob

John Overington

Janet Thornton

Affiliations

Soon will be listed here.

Abstract

Bioactive molecules such as drugs, pesticides and food additives are produced in large numbers by many commercial and academic groups around the world. Enormous quantities of data are generated on the biological properties and quality of these molecules. Access to such data - both on licensed and commercially available compounds, and also on those that fail during development - is crucial for understanding how improved molecules could be developed. For example, computational analysis of aggregated data on molecules that are investigated in drug discovery programmes has led to a greater understanding of the properties of successful drugs. However, the information required to perform these analyses is rarely published, and when it is made available it is often missing crucial data or is in a format that is inappropriate for efficient data-mining. Here, we propose a solution: the definition of reporting guidelines for bioactive entities - the Minimum Information About a Bioactive Entity (MIABE) - which has been developed by representatives of pharmaceutical companies, data resource providers and academic groups.

Citing Articles

EMBL's European Bioinformatics Institute (EMBL-EBI) in 2023.

Thakur M, Buniello A, Brooksbank C, Gurwitz K, Hall M, Hartley M Nucleic Acids Res. 2023; 52(D1):D10-D17.

PMID: 38015445 PMC: 10767983. DOI: 10.1093/nar/gkad1088.

Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments.

Tanoli Z, Aldahdooh J, Alam F, Wang Y, Seemab U, Fratelli M Brief Bioinform. 2021; 23(1).

PMID: 34472587 PMC: 8769689. DOI: 10.1093/bib/bbab350.

Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments.

Tanoli Z, Aldahdooh J, Alam F, Wang Y, Seemab U, Fratelli M bioRxiv. 2020; .

PMID: 33300000 PMC: 7724669. DOI: 10.1101/2020.12.03.409409.

QSAR without borders.

Muratov E, Bajorath J, Sheridan R, Tetko I, Filimonov D, Poroikov V Chem Soc Rev. 2020; 49(11):3525-3564.

PMID: 32356548 PMC: 8008490. DOI: 10.1039/d0cs00098a.

NutriGenomeDB: a nutrigenomics exploratory and analytical platform.

Martin-Hernandez R, Reglero G, Ordovas J, Davalos A Database (Oxford). 2019; 2019.

PMID: 31665759 PMC: 6821151. DOI: 10.1093/database/baz097.

References

Qi D, King R, Hopkins A, Bickerton G, Soldatova L . An ontology for description of drug discovery investigations. J Integr Bioinform. 2010; 7(3). DOI: 10.2390/biecoll-jib-2010-126. View

Vizcaino J, Martens L, Hermjakob H, Julian R, Paton N . The PSI formal document process and its implementation on the PSI website. Proteomics. 2007; 7(14):2355-7. DOI: 10.1002/pmic.200700064. View

Zhang Z, Grigorov M . Similarity networks of protein binding sites. Proteins. 2005; 62(2):470-8. DOI: 10.1002/prot.20752. View

Croft D, OKelly G, Wu G, Haw R, Gillespie M, Matthews L . Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2010; 39(Database issue):D691-7. PMC: 3013646. DOI: 10.1093/nar/gkq1018. View

Schmidtke P, Barril X . Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J Med Chem. 2010; 53(15):5858-67. DOI: 10.1021/jm100574m. View

. The Gene Ontology in 2010: extensions and refinements. Nucleic Acids Res. 2009; 38(Database issue):D331-5. PMC: 2808930. DOI: 10.1093/nar/gkp1018. View

Bourbeillon J, Orchard S, Benhar I, Borrebaeck C, de Daruvar A, Dubel S . Minimum information about a protein affinity reagent (MIAPAR). Nat Biotechnol. 2010; 28(7):650-3. DOI: 10.1038/nbt0710-650. View

Hopkins A, Groom C . The druggable genome. Nat Rev Drug Discov. 2002; 1(9):727-30. DOI: 10.1038/nrd892. View

Berriman M, Haas B, LoVerde P, Wilson R, Dillon G, Cerqueira G . The genome of the blood fluke Schistosoma mansoni. Nature. 2009; 460(7253):352-8. PMC: 2756445. DOI: 10.1038/nature08160. View

10.

Yeung B, Zou B, Rottmann M, Lakshminarayana S, Ang S, Leong S . Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem. 2010; 53(14):5155-64. PMC: 6996867. DOI: 10.1021/jm100410f. View

11.

Halgren T . Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model. 2009; 49(2):377-89. DOI: 10.1021/ci800324m. View

12.

Aranda B, Blankenburg H, Kerrien S, Brinkman F, Ceol A, Chautard E . PSICQUIC and PSISCORE: accessing and scoring molecular interactions. Nat Methods. 2011; 8(7):528-9. PMC: 3246345. DOI: 10.1038/nmeth.1637. View

13.

Inglese J, Shamu C, Guy R . Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol. 2007; 3(8):438-41. DOI: 10.1038/nchembio0807-438. View

14.

Kerrien S, Orchard S, Montecchi-Palazzi L, Aranda B, Quinn A, Vinod N . Broadening the horizon--level 2.5 of the HUPO-PSI format for molecular interactions. BMC Biol. 2007; 5:44. PMC: 2189715. DOI: 10.1186/1741-7007-5-44. View

15.

Overington J, Al-Lazikani B, Hopkins A . How many drug targets are there?. Nat Rev Drug Discov. 2006; 5(12):993-6. DOI: 10.1038/nrd2199. View

16.

Seiler K, George G, Pat Happ M, Bodycombe N, Carrinski H, Norton S . ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res. 2007; 36(Database issue):D351-9. PMC: 2238881. DOI: 10.1093/nar/gkm843. View

17.

Sayers E, Barrett T, Benson D, Bolton E, Bryant S, Canese K . Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2010; 39(Database issue):D38-51. PMC: 3013733. DOI: 10.1093/nar/gkq1172. View

18.

Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C . Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001; 29(4):365-71. DOI: 10.1038/ng1201-365. View

19.

Hajduk P, Huth J, Tse C . Predicting protein druggability. Drug Discov Today. 2005; 10(23-24):1675-82. DOI: 10.1016/S1359-6446(05)03624-X. View

20.

. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res. 2010; 39(Database issue):D214-9. PMC: 3013648. DOI: 10.1093/nar/gkq1020. View